SCHEMBL13735624

SCHEMBL13735624

O=C(O)C1CC2CCC(C1)O2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
LMNA P02545 3/20 0.39
PMP22 Q01453 2/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
GABRA4 P48169 1/20 0.39
GABRE P78334 1/20 0.39
GABRA6 Q16445 1/20 0.39
GABRG1 Q8N1C3 1/20 0.39
GABRG3 Q99928 1/20 0.39
GABRQ Q9UN88 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4970270 0.89 CYP2C19 (0.39) TSHRLMNAPMP22GABRPGABRD
SCHEMBL31085303 0.77 HDAC3 (0.36) KDM4ECYP2D6SMN1; SMN2HDAC3HDAC1
SCHEMBL31085278 0.77 HDAC3 (0.36) KDM4ECYP2D6SMN1; SMN2HDAC3HDAC1
SCHEMBL31085277 0.77 HDAC3 (0.36) KDM4ECYP2D6SMN1; SMN2HDAC3HDAC1
Bicarbonate SCHEMBL11026715 0.74 MAPK1 (0.42) TSHRLMNAPMP22KDM4EGMNN
SCHEMBL23366184 0.73 CYP2C19 (0.50) TSHRLMNAPMP22GABRPGABRD
SCHEMBL6542917 0.73 CYP2C19 (0.50) TSHRLMNAPMP22GABRPGABRD
SCHEMBL375124 0.73 CYP2C19 (0.50) TSHRLMNAPMP22GABRPGABRD
SCHEMBL19902117 0.73 CYP2C19 (0.50) TSHRLMNAPMP22GABRPGABRD
SCHEMBL8204743 0.73 CYP2C19 (0.50) TSHRLMNAPMP22GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117500802-A LACTIVICIN compounds, their preparation and their use as antibacterial agents 费多拉制药有限公司 2024-02-02 CN claimed
US-11780832-B2 Lactivicin compounds, their preparation and use as antibacterial agents FEDORA PHARMACEUTICALS INC. (CA) 2023-10-10 US claimed
WO-2026090509-A1 SPIRO HETEROCYCLIC CDK2 INHIBITORS ARCHITECT THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
EP-4720035-A1 LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF LIBERATE BIO, INC. (US) 2026-04-08 EP disclosed
EP-4436667-B1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2026-01-21 EP disclosed
US-12528804-B2 Lactivicin compounds, their preparation and use as antibacterial agents FEDORA PHARMACEUTICALS INC. (CA) 2026-01-20 US disclosed
CN-114948963-B Benzolactam compounds as protein kinase inhibitors 大冢制药株式会社 2025-05-27 CN disclosed
US-20250011300-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2025-01-09 US disclosed
WO-2024249525-A1 LIPID COMPOUNDS, COMPOSITIONS, AND USES THEREOF LIBERATE BIO, INC. (US) 2024-12-05 WO disclosed
EP-4247800-B1 N-SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2024-11-13 EP disclosed
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-11-07 US disclosed
WO-2017068412-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-04-27 WO disclosed
US-20160347761-A1 INHIBITORS OF HISTONE DEACETYLASE THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) 2016-12-01 US disclosed
US-9447030-B2 Inhibitors of histone deacetylase MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2016-09-20 US disclosed
US-20160251351-A1 INHIBITORS OF HISTONE DEACETYLASE THE BROAD INSTITUTE, INC. (US) 2016-09-01 US disclosed
US-9365498-B2 Inhibitors of histone deacetylase THE BROAD INSTITUTE, INC. (US) 2016-06-14 US disclosed
US-20140080800-A1 Inhibitors of Histone Deacetylase MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2014-03-20 US disclosed
US-20140080802-A1 Inhibitors of Histone Deacetylase MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2014-03-20 US disclosed
EP-2701699-A1 INHIBITORS OF HISTONE DEACETYLASE The Broad Institute, Inc. (US) 2014-03-05 EP disclosed
WO-2012149540-A1 INHIBITORS OF HISTONE DEACETYLASE THE BROAD INSTITUTE INC (US) 2012-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080800-A1 Inhibitors of Histone Deacetylase HDAC2, HDAC1, HDAC11 TSHR 3090/4885LMNA 1689/4885PMP22 3864/4885
US-20250011300-A1 PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS ABL1, Q6ZSR9, NQO2 TSHR 2563/4885LMNA 2830/4885PMP22 1502/4885
US-20160347761-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC2, HDAC1, HDAC11 TSHR 3090/4885LMNA 1689/4885PMP22 3864/4885
US-20160251351-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC2, HDAC11 TSHR 3027/4885LMNA 1406/4885PMP22 4043/4885
US-20140080802-A1 Inhibitors of Histone Deacetylase HDAC2, HDAC1, HDAC11 TSHR 3090/4885LMNA 1689/4885PMP22 3864/4885
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 TSHR 1191/4885LMNA 820/4885PMP22 3358/4885
US-12528804-B2 Lactivicin compounds, their preparation and use as antibacterial agents LCT, LPO, CLSPN TSHR 890/4885LMNA 1567/4885PMP22 4568/4885
US-11780832-B2 Lactivicin compounds, their preparation and use as antibacterial agents LCT, VIP, LPO TSHR 4297/4885LMNA 662/4885PMP22 4204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.